REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker ...
Presentation Title: The ADELA study: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA)+ Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2-Advanced Breast Cancer ...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused ...
Journalist Amy Robach reflects on her journey—and how women like Rebecca are reclaiming their lives after diagnosis.
Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...
Jazz Pharma to present pivotal phase 3 results of Ziihera combinations in first-line HER2-positive locally advanced or metastatic GEA at 2026 ASCO GI symposium: Dublin Thursday, D ...
The bispecific HER2-directed antibody-drug conjugate (ADC) TQB2102 has demonstrated robust antitumor activity and a positive safety profile in the phase 2 TQB2102-II-01 trial (NCT06198751), showing ...
MedPage Today on MSN
Transformation of Lung Cancer; What the OR Team Had to Say; Microplastics and Cancer
The FDA granted traditional approval to pirtobrutinib (Jaypirca) for relapsed/refractory chronic lymphocytic leukemia/small ...
Abemaciclib is the first CDK4/6 inhibitor to produce a significant overall survival benefit in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer, ...
The findings suggest that the HER2DX assay could help clinicians decide on the appropriate use of chemotherapy in older patients, study researchers wrote.
Friends, have you heard of triple-negative breast cancer [TNBC]? It’s a particularly aggressive type of breast cancer that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback